Biopharmaceutical News and Research

RSS

OXiGENE regains compliance for continued listing on NASDAQ Global Market

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)

7 Apr 2010

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the closing of the underwriters' exercise of their over-allotment option to purchase an additional 604,492 shares of Anthera's common stock, at a price of $7.00 per share.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer to discover novel therapeutic agents to treat multi-drug resistant tuberculosis.

7 Apr 2010

New web-based technology platform for late phase clinical research

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has introduced a new web-based technology platform for late phase clinical research to meet the expanding regulatory and commercialization needs of the biopharmaceutical industry.

6 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring biotech company Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

6 Apr 2010

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye Pharmaceutical subsidiary ("Erye") recently received approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium.

5 Apr 2010

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.

5 Apr 2010

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC.

5 Apr 2010

Selecta Biosciences raises $15M in new Series C financing round

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

Kyto Biopharma Inc., is a Florida biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

3 Apr 2010

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

Ricerca Biosciences, Life Science Partner announce business development agreement

Ricerca Biosciences, a preclinical contract research drug development company, is pleased to announce a business development agreement with Life Science Partner (LSP) Co., Ltd., of Tokyo, Japan. Ricerca offers a unique spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.

1 Apr 2010

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities Commission for a best efforts offering to sell up to $40.0 million of units consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock. The offering anticipates including shares of common stock to be sold by selling stockholders.

1 Apr 2010

Biopharmaceutical News and Research

OXiGENE regains compliance for continued listing on NASDAQ Global Market

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

New web-based technology platform for late phase clinical research

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

StockPreacher.com releases investment report on Repros Therapeutics

Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Selecta Biosciences raises $15M in new Series C financing round

Clinical utility and pharmacological action of MN-166 in treatment of MS

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

U.S. Court upholds validity of Eli Lilly's Gemzar compound patent

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Ricerca Biosciences, Life Science Partner announce business development agreement

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

GeoVax Labs files registration statement for offering to sell up to $40.0 million of units

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News